Federica Miglietta
0000-0001-6203-874X
5 papers found
Refreshing results…
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
An overview of immune checkpoint inhibitors in breast cancer
Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Breast Cancer
Missing publications? Search for publications with a matching author name.